A Study of Humanized CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell ALL and B-cell NHL

This study is testing a humanized version of CAR-T cell therapy — where a patient's immune cells are genetically engineered to target a protein called CD19 found on cancer cells — for patients whose B-cell leukemia or lymphoma has come back or is not responding to treatment. **You may be eligible if...** - You are between 3 and 70 years old - You have relapsed or treatment-resistant CD19-positive B-cell leukemia (B-ALL) or B-cell lymphoma (B-NHL) - Prior standard chemotherapy has not worked, or the disease came back within 12 months of first remission, or has relapsed at least twice **You may NOT be eligible if...** - You have uncontrolled serious infection - You have significant heart, liver, or kidney problems - You are pregnant or breastfeeding - You previously received CAR-T therapy targeting CD19 with severe side effects Talk to your doctor to see if this trial is right for you.